Results
1 -
10 of
84Update on New Treatments for Idiopathic Pulmonary Fibrosis, Current Emergency and Hospital Medicine Reports Nintedanib more cost effective than pirfenidone for IPF?, PharmacoEconomics & Outcomes News Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme, Journal of Neuro-Oncology Idiopathic Pulmonary Fibrosis, Treatment of Cystic Fibrosis and Other Rare Lung Diseases Treatment of Idiopathic Pulmonary Fibrosis, Guide to Clinical Management of Idiopathic Pulmonary Fibrosis Pharmacotherapy of IPF Using Antifibrotic Compounds, Idiopathic Pulmonary Fibrosis Therapie der Lungenfibrose, Der Internist Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis, Cancer Chemotherapy and Pharmacology First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of?????50??% of Predicted Value, Lung